Cost-Effectiveness of an Extended Home Visit Program for Oxygen-Dependent COPD Patients

References

1. 1.↵
   Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;I(8222):681-686.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93(3):391-398.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   GOLD. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018 [Mar 19, 2020]. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed July 12, 2021.
4. 4.↵
   1. Foo J,
   2. Landis SH,
   3. Maskell J,
   4. Oh Y-M,
   5. van der Molen T,
   6. Han MK,
   7. et al

   . Continuing to confront COPD International Patient Survey: economic impact of COPD in 12 countries. PLoS One 2016;11(4):e0152618.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Cullen DL

   . Long term oxygen therapy adherence and COPD: what we don't know. Chron Respir Dis 2006;3(4):217-222.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Pepin JL,
   2. Barjhoux CE,
   3. Deschaux C,
   4. Brambilla C

   . Long-term oxygen therapy at home. Compliance with medical prescription and effective use of therapy. ANTADIR Working Group on Oxygen Therapy. Association Nationale de Traitement a Domicile Des Insuffisants Respiratories. Chest 1996;109(5):1144-1150.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Peckham DG,
   2. McGibbon K,
   3. Tonkinson J,
   4. Plimbley G,
   5. Pantin C

   . Improvement in patient adherence with long-term oxygen therapy following formal assessment with training. Respir Med 1998;92(10):1203-1206.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Rizzi M,
   2. Grassi M,
   3. Pecis M,
   4. Andreoli A,
   5. Taurino AE,
   6. Sergi M,
   7. Fanfulla F

   . A specific home care program improves the survival of patients with chronic obstructive pulmonary disease receiving long term oxygen therapy. Arch Phys Med Rehabil 2009;90(3):395-401.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Lacasse Y,
   2. Bernard S,
   3. Maltais F

   . Eligibility for home oxygen programs and funding across Canada. Can Respir J 2015;22(6):324-330.

   OpenUrlPubMed
10. 10.↵
    1. Hardinge M,
    2. Annandale J,
    3. Bourne S,
    4. Cooper B,
    5. Evans A,
    6. Freeman D,
    7. et al

    ; British Thoracic Society Home Oxygen Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for home oxygen use in adults. Thorax 2015;70(Suppl 1):i1-i433.

    OpenUrlPubMed
11. 11.↵
    1. Bourbeau J,
    2. Julien M,
    3. Maltais F,
    4. Rouleau M,
    5. Beaupre A,
    6. Begin R,
    7. et al

    ; Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003;163(5):585-591.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Eaton TE,
    2. Grey C,
    3. Garrett JE

    . An evaluation of short-term oxygen therapy: the prescription of oxygen to patients with chronic lung disease hypoxic at discharge from hospital. Respir Med 2001;95(7):582-587.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Levi-Valensi P,
    2. Weitzenblum E,
    3. Pedinielli JL,
    4. Racineux JL,
    5. Duwoos H

    . Three-month follow-up of arterial blood gas determinations in candidates for long-term oxygen therapy. A multicentric study. Am Rev Respir Dis 1986;133(4):547-551.

    OpenUrlPubMed
14. 14.↵
    1. Gauthier A,
    2. Bernard S,
    3. Bernard E,
    4. Simard S,
    5. Maltais F,
    6. Lacasse Y

    . Adherence to long-term oxygen therapy in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2019;16:1479972318767724.

    OpenUrl
15. 15.↵
    1. Beck JR,
    2. Pauker SG,
    3. Gottlieb JE,
    4. Klein K,
    5. Kassirer JP

    . A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med 1982;73(6):889-897.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Lacasse Y,
    2. Bernard S,
    3. Martin S,
    4. Boivin M,
    5. Maltais F

    . Utility scores in patients with oxygen-dependent COPD: a case-control study. COPD 2015;12(5):510-515.

    OpenUrl
17. 17.↵
    CADTH: Canadian Agency for Drugs and Technologies in Health. 2017. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH. https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada. Accessed July 12, 2021.
18. 18.↵
    1. Al MJ

    . Cost-effectiveness acceptability curves revisited. Pharmacoeconomics 2013;31(2):93-100.

    OpenUrl
19. 19.↵
    1. Laupacis A,
    2. Feeny D,
    3. Detsky AS,
    4. Tugwell PX

    . How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146(4):473-481.

    OpenUrlAbstract
20. 20.↵
    1. Skedgel C,
    2. Wranik D,
    3. Hu M

    . The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the Pan-Canadian Oncology Drug Review 2011-2017. Pharmacoeconomics 2018;36(4):467-475.

    OpenUrl
21. 21.↵
    1. Drummond MF,
    2. Richardson WS,
    3. O'Brien BJ,
    4. Levine M,
    5. Heyland D

    . Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1997;277(19):1552-1557.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Oba Y

    . Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease. Am J Manag Care 2009;15(2):97-104.

    OpenUrlPubMed
23. 23.↵
    1. Chandra K,
    2. Blackhouse G,
    3. McCurdy BR,
    4. Bornstein M,
    5. Campbell K,
    6. Costa V,
    7. et al

    . Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Ont Health Technol Assess Ser 2012;12(12):1-61.

    OpenUrlPubMed
24. 24.↵
    1. Jodar-Sanchez F,
    2. Ortega F,
    3. Parra C,
    4. Gomez-Suarez C,
    5. Bonachela P,
    6. Leal S,
    7. et al

    . Cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J Telemed Telecare 2014;20(6):307-316.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Dunne PJ

    . The demographics and economics of long-term oxygen therapy. Respir Care 2000;45(2):223-228; discussion 228-230.

    OpenUrlPubMed